{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-090384","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.200374+00:00","generated_at":"2026-05-18T18:21:05.804712+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rani Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure ends Dec 17","bullets":["Received Nasdaq notice on June 20, 2025 for non-compliance with $1.00 minimum bid price (30 consecutive business days below $1.00).","Must regain compliance by December 17, 2025 by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.","If not cured, may transfer to Nasdaq Capital Market for an additional 180-day period, subject to meeting other initial listing standards.","Company will monitor bid price and consider options, including a potential reverse stock split.","No assurance that the company will regain compliance or that Nasdaq will grant an extension."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-090384","json":"https://secwatch.observer/filing/0000950170-25-090384.json","markdown":"https://secwatch.observer/filing/0000950170-25-090384.md","text":"https://secwatch.observer/filing/0000950170-25-090384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017025090384/0000950170-25-090384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017025090384/rani-20250620.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T18:21:05.804712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"046c9de2e268a1fa71d9345c3158b530569bfe94","claim":"Rani Therapeutics Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"June 20, 2025, Rani Therapeutics Holdings, Inc. (“Company”) received a letter (“Notice”) from the Nasdaq Stock Exchange LLC (“Nasdaq”), notifying Company that, based on the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). Under Na","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000095017025090384/0000950170-25-090384-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}